T1	Participants 137 162	metastatic breast cancer.
T2	Participants 284 402	patients with metastatic breast cancer, where the alternate crossover monotherapy (GD→C or CD→G) was predetermined
T3	Participants 864 999	RESULTS Despite over-accrual of 475 patients, the trial matured with only 324 of 385 planned TtP events due to patient discontinuations
